Your browser doesn't support javascript.
loading
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".
Affronti, Mary Lou; Herndon, James E; Patel, Mallika P.
Afiliação
  • Affronti ML; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, 047 Baker House, Trent Drive, DUMC Box 3624, Durham, NC, 27710, USA. mary.affronti@duke.edu.
  • Herndon JE; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. mary.affronti@duke.edu.
  • Patel MP; Duke University School of Nursing, Duke University, Durham, NC, USA. mary.affronti@duke.edu.
Support Care Cancer ; 28(12): 5591-5592, 2020 12.
Article em En | MEDLINE | ID: mdl-32885313
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Glioma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Support Care Cancer Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Glioma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Support Care Cancer Ano de publicação: 2020 Tipo de documento: Article